
Gilead inks deal with Canadian antibody discovery firm AbCellera
pharmafile | June 14, 2019 | News story | Medical Communications | AbCellera, Gilead, monoclonal antibodies, pharma
Gilead has entered into an agreement with Canadian monoclonal antibody discovery firm AbCellera.
The two firms will take part in a cross border collaboration to support the discovery of new therapeutic antibody candidates for infectious diseases.
Under the terms of the agreement AbCellera will receive upfront and research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties on net sales of products.
“AbCellera is dedicated to partnering with the most innovative companies to discover breakthrough therapies, and we look forward to adding our technology to Gilead’s early research efforts,” commented Carl Hansen, President and CEO of AbCellera.
Using a sutie of proprietary technologies, AbCellera will be looking for ultra-rare antibodies with specific properties defined by Gilead.
Louis Goss
Related Content

AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials
AstraZeneca’s tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) in two …

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …





